We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
-10.74%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$582M
AUM Growth
-$123M
Cap. Flow
+$8.6M
Cap. Flow %
1.48%
Top 10 Hldgs %
47.58%
Holding
53
New
6
Increased
26
Reduced
8
Closed
10
Avg Time Held
1.1 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$577M
$57.9M 9.95%
7,648,268
– –
2021 Q1
16 quarters
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$8.81B
$33.3M 5.72%
+100,415
New +$33M
2025 Q1
0 quarters
ZLAB icon
3
Zai Lab
ZLAB
$2.63B
$30.1M 5.18%
833,659
+33,659
+4% +$1.04M
2024 Q4
1 quarter
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.37B
$24.3M 4.18%
1,105,444
+26,128
+2% +$685K
2024 Q1
4 quarters
LNTH icon
5
Lantheus
LNTH
$6.68B
$22.7M 3.9%
232,387
-3,826
-2% -$358K
2024 Q2
3 quarters
PTCT icon
6
PTC Therapeutics
PTCT
$4.71B
$22.4M 3.85%
439,977
+5,210
+1% +$260K
2024 Q3
2 quarters
NTRA icon
7
Natera
NTRA
$39.6B
$22.2M 3.82%
157,047
-3,579
-2% -$575K
2024 Q1
4 quarters
TRVI icon
8
Trevi Therapeutics
TRVI
$1.9B
$21.6M 3.71%
3,428,366
+333,470
+11% +$1.59M
2024 Q1
4 quarters
CRNX icon
9
DELISTED
Crinetics Pharmaceuticals
CRNX
$21.2M 3.64%
631,964
+14,929
+2% +$558K
2021 Q3
14 quarters
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$21.1M 3.62%
714,224
+11,243
+2% +$350K
2024 Q2
3 quarters
GH icon
11
Guardant Health
GH
$19.7B
$18.9M 3.24%
442,656
-10,083
-2% -$435K
2024 Q2
3 quarters
UTHR icon
12
United Therapeutics
UTHR
$23.6B
$18.2M 3.12%
58,907
+35,907
+156% +$12.3M
2024 Q4
1 quarter
SPRY icon
13
ARS Pharmaceuticals
SPRY
$298M
$16.5M 2.84%
+1,313,104
New +$15.8M
2025 Q1
0 quarters
CMPX icon
14
Compass Therapeutics
CMPX
$124M
$16M 2.76%
8,442,783
-125,113
-1% -$333K
2024 Q1
4 quarters
JANX icon
15
Janux Therapeutics
JANX
$617M
$15.3M 2.63%
567,193
+337,193
+147% +$12.7M
2024 Q3
2 quarters
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$1.68B
$14.4M 2.48%
398,445
+7,427
+2% +$309K
2024 Q1
4 quarters
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$942M
$12.3M 2.12%
316,049
+819
+0.3% +$35.3K
2023 Q2
7 quarters
WVE icon
18
Wave Life Sciences
WVE
$505M
$12.2M 2.1%
1,509,580
+20,343
+1% +$222K
2024 Q3
2 quarters
RVMD icon
19
Revolution Medicines
RVMD
$34.9B
$11.2M 1.93%
317,083
+3,266
+1% +$133K
2021 Q3
14 quarters
ALKS icon
20
Alkermes
ALKS
$7.55B
$11.1M 1.92%
+337,603
New +$11M
2025 Q1
0 quarters
OLMA icon
21
Olema Oncology
OLMA
$615M
$11M 1.89%
2,930,446
+17,896
+0.6% +$90K
2023 Q2
7 quarters
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$218M
$10.8M 1.86%
1,618,265
+597,706
+59% +$5.91M
2024 Q3
2 quarters
ITOS icon
23
DELISTED
iTeos Therapeutics
ITOS
$10.4M 1.79%
1,745,943
– –
2020 Q3
18 quarters
RNAC icon
24
Cartesian Therapeutics
RNAC
$187M
$10.4M 1.79%
790,779
+69,640
+10% +$1.24M
2024 Q2
3 quarters
TWST icon
25
Twist Bioscience
TWST
$7.04B
$10.3M 1.76%
261,215
-6,282
-2% -$283K
2024 Q3
2 quarters

Similar funds

MPM BioImpact's Q1 2025 Portfolio in Review

As of Q1 2025, MPM BioImpact held 53 positions worth $582M, down 17% from $704M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

MPM BioImpact's Q1 2025 filing shows 6 new, 26 increased, 8 reduced and 10 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M. The largest sale was Insmed, an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q1 2025 buy was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M.
  • MPM BioImpact added most to Janux Therapeutics in Q1 2025, an estimated $12.7M increase.
  • MPM BioImpact's biggest Q1 2025 reduction was ALX Oncology, cutting an estimated $1.01M.
  • MPM BioImpact fully exited Insmed in Q1 2025, selling an estimated $26.9M.
  • MPM BioImpact's ten largest holdings make up 48% of its $582M portfolio in Q1 2025.
  • MPM BioImpact opened 6 new positions and closed 10 in Q1 2025.
  • MPM BioImpact's portfolio value fell 17% quarter-over-quarter to $582M.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.